NVAX Q3 2021 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$179M+13.9% YoY

Gross Profit

$179M100.0% margin

Operating Income

-$307M-171.7% margin

Net Income

-$322M-180.3% margin

EPS (Diluted)

$-4.31

QoQ Revenue Growth

-40.0%

Cash Flow

Operating Cash Flow

-$142M

Free Cash Flow

-$154M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$2.1B

Stockholders' Equity

$461M

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$179M	$157M	+13.9%
Gross Profit	$179M	$157M	+13.9%
Operating Income	-$307M	-$194M	-58.4%
Net Income	-$322M	-$197M	-63.4%

Revenue Segments

Government Contract

$98M55%

Grant

$41M23%

Royalties and Other

$40M22%